Site Sponsors
  • Strem Chemicals - Nanomaterials for R&D
  • Park Systems - Manufacturer of a complete range of AFM solutions
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD

Parios Regenerative Sciences Inks License Deal with Brown University for Organic Nanotechnology

Published on November 2, 2012 at 5:38 AM

Parios Regenerative Sciences, Inc., a privately held medical device company specializing in the development of biomaterials for skin repair and regeneration, has entered into a comprehensive license agreement with Brown University, licensing exclusive rights to a proprietary organic nanotechnology for use in dermatological applications. The nanotechnology, Oderm™, has clinical relevance in cosmetic skin rejuvenation, dermatological applications, and advanced wound care.

"Our agreement with Brown is a significant milestone for Parios," stated Mark Johanson, President and Chief Executive Officer.  "The Oderm™ technology shows great promise in advancing the field of skin regeneration for both aesthetic and wound care applications. We are committed to the commercial and clinical success of this novel skin care product."

Under the terms of the agreement, Parios has obtained an exclusive license to a platform of intellectual property and technologies co-developed by Dr. Thomas Webster, former associate professor of engineering at Brown.

"We are enthusiastic to have partnered with such an experienced and accomplished team at Parios," said Katherine Gordon, Managing Director of the Brown University Technology Ventures Office, "and look forward to successful development of the product."

The Oderm™ biomaterial consists of organic nanomolecules that self-assemble into structures resembling collagen – a major component of skin. Using these organic structures to replace degenerated or damaged skin encourages the growth of natural tissue. The company's goal is to provide off-the-shelf materials that regenerate healthy and functional tissue and offer a repair that lasts the life of the patient.

Source: Parios Regenerative Sciences, Inc.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit